Veracyte follows IPO with massive Dx revenue growth

Veracyte CEO Bonnie Anderson

Veracyte ($VCYT) released its first quarterly earnings report as a public company this week. The molecular diagnostics company has a lot to celebrate. Revenue reached $5.6 million for the 2013 third quarter, up 74% from $3.2 million booked over the same period a year ago. Much wider adoption of the California company's Afirma Thyroid FNA Analysis test helped drive the increase. Veracyte's CLIA-certified lab processed 12,417 FNA samples during the quarter, versus 7,052 in the third quarter of 2012. Net losses reached $6.3 million, up from $4.9 million in the 2012 third quarter--a number that reflects an expanded commercial ramp-up. The Afirma test combines a specialized cytopathology assessment and a gene-expression test to determine whether a thyroid nodule is benign or cancerous. "In the near term we are really focused on diving growth at the top line and expanding our portfolio beyond the thyroid product to include other indications," CEO Bonnie Anderson told FierceDiagnostics. Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.